Please enable Javascript
RLT-PSMA
Radioligand therapy prostate-specific membrane antigen
Advertisement
FDA Approves New Indication for Illuccix to Include Patient Selection
Emily Menendez
Prostate Cancer
|
March 16, 2023
The new indication will improve access to imaging for approximately 32,000 candidates for radioligand therapy in the US.
Read More
RLT Administration in the Community Setting
Scott Tagawa, MD, MS, FACP
RLT-PSMA
|
February 22, 2023
Scott Tagawa, MD, MS, FACP, shares what needs to happen for radionuclide therapy to make its way into the community setting.
View More
Lutetium-177–PSMA-617: Appropriate and Potential Off-Label Utility
Scott Tagawa, MD, MS, FACP
RLT-PSMA
|
February 22, 2023
Scott Tagawa, MD, MS, FACP, highlights what clinicians must know prior to recommending Lutetium-177–PSMA-617 to patients.
View More
RLT-PSMA in Development
Gary Ulaner, MD, PhD, FACNM
RLT-PSMA
|
January 24, 2023
Dr. Ulaner highlights the line(s) of therapy in which novel RLT-PSMA agents are being developed.
View More
Safety and Efficacy of 177Lu-PSMA-617
Gary Ulaner, MD, PhD, FACNM
RLT-PSMA
|
January 24, 2023
Dr. Ulaner explains the data that led to the FDA approval of 177Lu-PSMA-617 and the safety profile of this drug.
View More
Novel PRO Tool for Patients With Prostate Cancer After Radionuclide Therapy
Zachary Bessette
RLT-PSMA
|
January 23, 2023
Moffitt Cancer Center developed the first PRO measure for patients receiving RNT to guide treatment and improve QoC.
Read More
Safety and Efficacy of PSMA-RLT in Early-Stage and Hormone-Sensitive Prostate Cancer
Emily Menendez
RLT-PSMA
|
January 12, 2023
While PSMA-RLT is typically used during later disease stages, patients in earlier disease stages may benefit as well.
Read More
Improving Genetic Testing Compliance for Prostate Cancer: A Single-Practice Study
Zachary Bessette
RLT-PSMA
|
January 4, 2023
Implementing a genetic testing model for prostate cancer patients can improve detection rates for actionable mutations.
Read More
Assessing 3D Organoids in Personalized Medicine for Prostate Cancer
Robert Dillard
RLT-PSMA
|
December 21, 2022
A study sought to assess organoids and short-term ex vivo cultures of prostate cancer.
Read More
A Validated Risk Model for Personalized Prostate Cancer Risk
Robert Dillard
RLT-PSMA
|
December 21, 2022
Researchers developed the first validated risk model for discerning personalized prostate cancer risks.
Read More
Genetic Risk Scoring in Prostate Cancer for Men of African Ancestry
Robert Dillard
RLT-PSMA
|
December 21, 2022
A risk score can predict prostate cancer in men of African ancestry.
Read More
People with a Family History of Prostate Cancer May Have Better Survival
Robert Dillard
RLT-PSMA
|
December 21, 2022
A greater family history of prostate cancer is associated with a lower risk of mortality.
Read More
Challenges & Advances in Phenotypic Precision Medicine
Jacqueline T. Brown, MD
RLT-PSMA
|
December 21, 2022
Dr. Jacqueline Brown talks about current challenges and advances in phenotypic precision medicine and treatment strategies.
View More
Fluorine-18 PSMA-1007 PET/CT for PCa Risk Stratification
Emily Menendez
RLT-PSMA
|
December 20, 2022
Researchers analyzed 18F-PSMA-1007 PET/CT radiomics for their efficacy in determining tumor malignancy in prostate cancer.
Read More
Auto-Segmentation Model for PSMA PET-Delineated Tubarial Glands
Emily Menendez
RLT-PSMA
|
December 20, 2022
An auto-segmentation model for PSMA PET-delineated tubarial glands has been recently examined.
Read More
Effectiveness of 68Ga-PSMA PET/CT After Radical Therapy
Emily Menendez
RLT-PSMA
|
December 20, 2022
A recent study analyzed the efficacy of 68Ga-PSMA PET/CT in patients with a history of prostate cancer who have BCR.
Read More
AlphaBet Trial to Study 223Ra and [177Lu]Lu-PSMA for MCRPC
Emily Menendez
RLT-PSMA
|
December 20, 2022
The single-center, single-arm phase 1/2 AlphaBet trial will evaluate radium-223 & [177Lu]Lu-PSMA-I&T in patients with mCRPC.
Read More
Developments in Phenotypic Precision Medicine for Prostate Cancer
Jacqueline T. Brown, MD
RLT-PSMA
|
December 20, 2022
Dr. Jacqueline Brown talks about current developments in phenotypic precision medicine for prostate cancer.
View More
Updates on Phenotypic Precision Medicine for Prostate Cancer
Jacqueline T. Brown, MD
RLT-PSMA
|
December 19, 2022
Jacqueline T. Brown, MD talks about the current state of phenotypic precision medicine for advanced prostate cancer.
View More
Using PSMA PET to Evaluate Liver Metastases in CRPC
Emily Menendez
RLT-PSMA
|
November 29, 2022
The effectiveness of PSMA PET was compared with conventional imaging & liver biopsy, and a radiomic model was also evaluated.
Read More
Load More
Advertisement
Advertisement
Advertisement